b) The following adverse event listing is based on reports from clinical trials (Table 1, adverse events and laboratory abnormalities) and from the post-marketing surveillance (Table 2, reporting rates based on spontaneous adverse drug reaction reports classified as very common ≥ 1/ 10, common ≥ 1/ 100 to < 1/ 10, uncommon ≥ 1/ 1,000 to < 1/ 100, rare ≥ 1/ 10,000 to < 1/ 1,000, very rare < 1/ 10,000) of Extavia use.
b) Spodnja seznama neželenih učinkov temeljita na poročilih iz kliničnih raziskav (preglednica 1, neželeni učinki in nenormalni rezultati laboratorijskih preiskav) in iz postmarketinškega nadzora (preglednica 2, pogostnost navedb, ki temelji na spontanih prijavah neželenih učinkov zdravila; razvrstitev: zelo pogosto ≥1/ 10, pogosto ≥1/ 100 do < 1/ 10, občasno ≥1/ 1, 000 do < 1/ 100, redko ≥1/ 10, 000 do 1/ 1, 000, zelo redko < 1/ 10, 000)) uporabe zdravila Extavia.